Market News AIOpen the app

Pacira BioSciences is in a legal fight about royalty payments for its EXPAREL product.

RulesRead the original at SEC EDGAR
Bad for PCRX

The ruling says Pacira owes royalties on EXPAREL made with its 200-liter process, adding costs. Pacira keeps a favorable ruling for 45-liter batches, but that does not remove the payment duty.

PCRX · Pacira BioSciences, Inc.

AI read · Bad for PCRX

The AI's read

The restored payment duty can raise costs on EXPAREL made with the 200-liter process. Pacira still has a favorable ruling for 45-liter batches, and the court will recalculate the interest owed on those sales. The added royalty duty is the stronger change because the appeal reversed the prior ruling on the 200-liter process.

Get alerts for PCRX

Follow Pacira BioSciences, Inc. (PCRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PCRX
Free on the App Store and Google Play, or on the web.